# Advisor Review - GPT-5-mini

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-03T20:04:12.567462
**Route:** OpenRouter + LaTeX
**Tokens:** 16562 in / 1435 out
**Response SHA256:** f346c132e0cfb547

---

I checked the draft for fatal errors in the four required categories (Data-Design Alignment, Regression Sanity, Completeness, Internal Consistency), focusing only on issues that would embarrass the student or make the submission obviously unsalvageable. I inspected every table, each reported estimate, treatment timing, sample-period statements, and the appendix timing table.

Findings: I found no fatal errors.

Brief summary of checks performed (to justify PASS):
- Data-Design Alignment
  - Max treatment year (2023) ≤ max data year (ACS through 2023). Treatment coding rule (assign Q4 adoptions to the following calendar year) is explicitly stated and applied in the Detailed Treatment Timing table (Table in Appendix). The paper also explicitly discusses the income-measurement lag in ACS and correctly notes that very-late adoptions (Nevada 2021 → coded 2022; Rhode Island 2023) have limited or no true post-treatment income observations in the available ACS year; cohort-specific ATTs for these cohorts are appropriately excluded and this is documented in the Appendix (Table of group-time ATTs). Therefore there is no internal contradiction like “treatment in 2024 but data ends 2014–2023.”
  - For DiD/event-study: the paper acknowledges and tests for pre-trends using event studies and excludes cohort-specific ATTs where post-periods are insufficient. RDD-specific checks are not relevant.
  - Treatment definition is consistent between the adoption timeline table and the treatment-assignment rules described in the Data section and Appendix.

- Regression Sanity
  - All reported standard errors and coefficients in the regression tables are within plausible ranges for the outcomes used (log gaps and SDs). Example: SEs like 0.038, 0.089, etc., are reasonable relative to coefficients ~0.045–0.05. No SEs >1000 or >100×coefficient; no negative SEs; no "NA"/"Inf"/"NaN" entries.
  - R² values reported are between 0 and 1.
  - No obviously impossible coefficient magnitudes for log outcomes.

- Completeness
  - No placeholder strings (NA, TBD, TODO, XXX, PLACEHOLDER) appear in tables or the main text.
  - Regression tables report number of observations and standard errors; sample construction and unit of analysis are documented.
  - Figures and tables referenced in text have corresponding table/figure floats in the source; cohort exclusions and timing issues (e.g., late cohorts with few post-periods) are explicitly discussed and documented in Appendix tables.
  - Robustness checks described in the Methods/Results (alternative control groups, alternative estimators, placebo outcomes, Goodman-Bacon decomposition) are reported.

- Internal Consistency
  - Numbers cited in text match the tables (e.g., main ATT ~ -0.05 matches Table 3/Panel C and Appendix aggregation).
  - Treatment timing descriptions, assignment rules, and the detailed timing table in the appendix are consistent with one another.
  - Specification descriptions match column headers (TWFE vs. Callaway-Sant'Anna vs. Sun-Abraham), and sample sizes (state-year cells = 600) are used consistently.

Conclusion: No fatal errors detected under the advisor checklist.

ADVISOR VERDICT: PASS